key: cord-0913171-ae6p07sb
authors: Hartl, Lukas; Haslinger, Katharina; Angerer, Martin; Jachs, Mathias; Simbrunner, Benedikt; Bauer, David J. M.; Semmler, Georg; Scheiner, Bernhard; Eigenbauer, Ernst; Strassl, Robert; Breuer, Monika; Kimberger, Oliver; Laxar, Daniel; Trauner, Michael; Mandorfer, Mattias; Reiberger, Thomas
title: Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients
date: 2022-05-05
journal: Liver Int
DOI: 10.1111/liv.15274
sha: 660011ff2bb82e025c2200a2e22397983dc975c6
doc_id: 913171
cord_uid: ae6p07sb

BACKGROUND AND AIMS: The coronavirus disease of 2019 (COVID‐19) causes considerable mortality worldwide. We aimed to investigate the frequency and predictive role of abnormal liver chemistries in different age groups. METHODS: Patients with positive severe acute respiratory distress syndrome‐coronavirus‐2 (SARS‐CoV‐2) polymerase chain reaction (PCR) test between 03/2020‐07/2021 at the Vienna General Hospital were included. Patients were stratified for age: 18–39 vs. 40–69 vs. ≥70 years (y). Aspartate aminotransferase (AST), alanine‐aminotransferase (ALT), alkaline phosphatase (ALP), gamma‐glutamyl transferase (GGT) and total bilirubin (BIL) were recorded. RESULTS: 900 patients (18–39 years: 32.2%, 40–69 years: 39.7%, ≥70 years: 28.1%) were included. Number of comorbidities, median D‐dimer and C‐reactive protein increased with age. During COVID‐19, AST/ALT and ALP/GGT levels significantly increased. Elevated hepatocellular transaminases (AST/ALT) and cholestasis parameters (ALP/GGT/BIL) were observed in 40.3% (n = 262/650) and 45.0% (n = 287/638) of patients respectively. Liver‐related mortality was highest among patients with pre‐existing decompensated liver disease (28.6%, p < .001). 1.7% of patients without pre‐existing liver disease died of liver‐related causes, that is consequences of hepatic dysfunction or acute liver failure. Importantly, COVID‐19‐associated liver injury (16.0%, p < .001), abnormal liver chemistries and liver‐related mortality (6.5%, p < .001) were most frequent among 40–69 years old patients. Elevated AST and BIL after the first positive SARS‐CoV‐2 PCR independently predicted mortality in the overall cohort and in 40–69 years old patients. CONCLUSIONS: Almost half of the COVID‐19 patients exhibit abnormal hepatocellular and cholestasis‐related liver chemistries with 40–69 years old patients being at particularly high risk for COVID‐19‐related liver injury and liver‐related mortality. Elevated AST and BIL after SARS‐CoV‐2 infection are independent predictors of mortality, especially in patients aged 40–69 years.

The coronavirus disease of 2019 (COVID-19) pandemic, caused by severe acute respiratory distress syndrome-coronavirus-2 (SARS-CoV-2), is associated with substantial morbidity and mortality worldwide. 1 COVID-19 affects lungs, liver, intestinal and neuronal systems, causing acute respiratory distress syndrome (ARDS) and multiorgan failure. 2, 3 Risk factors for mortality due to COVID-19 include old age, obesity, male sex and pre-existing comorbidities including liver disease. [4] [5] [6] Previous studies have demonstrated liver enzyme abnormalities in a substantial number of patients with COVID-19. 7-11 Metaanalyses found liver transaminases to be elevated in approximately 20% of patients, and also reported increased parameters of cholestatic liver injury, that is alkaline phosphatase (ALP) in 6.1% and gamma-glutamyl transferase (GGT) in 21.1% of COVID-19 patients, respectively. 12, 13 Elevations of liver enzymes were more frequently observed in patients with severe courses of COVID-19 and in critically ill patients. [14] [15] [16] [17] In a large retrospective Chinese study, elevated levels of aspartate aminotransferase (AST) and direct bilirubin at hospital admission were identified as independent predictors of COVID-19associated mortality. 18 However, this study has some limitations, including the lack of detailed data on pre-existing liver disease and the severity of systemic inflammation. 19 Another study reported progressively increasing levels of hepatic transaminases in COVID-19 patients with severe courses of the disease. 20 Examining post-mortem liver biopsies of patients with SARS-CoV-2 infection, viral particles were detected in the cytoplasm of hepatocytes, directly linking hepatocellular infection with COVID-19-associated liver injury. 21 Next to direct SARS-CoV-2-mediated cytotoxicity, other pathomechanisms such as an excessive proinflammatory state, hypoxemia, drug-induced liver injury, coagulopathyassociated vascular dysfunction, cardiac congestion and sepsis are likely all contributing to liver injury in COVID-19. 3, 16 The aim of this study was to investigate (i) the rate of abnormal liver chemistries at the first blood withdrawal after the first positive SARS-CoV-2 polymerase chain reaction (PCR) test and (ii) the trajectory of hepatic transaminases in a large Austrian cohort of patients with COVID-19. Moreover, we set out to determine (iii) the impact of liver abnormalities on clinical outcome of patients with COVID-19 in different age strata. years, 40-69 years, and ≥70 years). Liver-related death was defined as death directly associated with liver-related complications. Preexisting liver disease was subdivided into non-advanced chronic liver disease (non-ACLD), compensated ACLD (cACLD) and decompensated ACLD (dACLD). Notably, due to the retrospective design of the study, not all parameters were available for every patient.

All parameters were assessed by standard laboratory assays.

For every parameter, the last available value prior to the positive SARS-CoV-2 PCR test (t0), as well as the first three available values after the positive SARS-CoV-2 PCR test (t1, t2 and t3 respectively) and the last available value (last) were recorded.

For parameters of hepatocellular (AST, ALT) and cholestatic liver injury (ALP, GGT, BIL), standard laboratory thresholds for men and women were used as upper limit of normal (ULN). Liver injury was defined as increased AST or ALT >3xULN or increased AP or BIL >2xULN, analogous to previous studies 18, 20 

The study was approved by the ethics committee (EC) of the Medical University of Vienna (EK1461/2020). It was performed in accordance with the current version of the Helsinki Declaration. Due to the retrospective design of the study, the EC waived the need for informed consent.

In total, 900 patients with positive SARS-CoV-2 PCR test were included in this study. 52.4% of patients were male. The median age was The main aetiologies included non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) in 58.3% (n = 35), alcoholrelated liver disease (ALD) in 16.7% (n = 10) and viral hepatitis in 8.3%

(n = 5) of patients with pre-existing liver disease. With progressive age, the prevalence of comorbidities, including pre-existing liver disease, arterial hypertension, diabetes mellitus, dyslipidemia, cardiovascular disease, chronic renal deficiency, lung disease and malignancy increased.

The rate of obesity was highest in 40-69 years old patients ( Table 1) .

At the blood withdrawal after the first positive SARS-CoV-2 PCR test, 10 Platelet count and albumin levels decreased throughout the age strata.

Creatinine levels were significantly increased in patients ≥70 years. Ddimer and CRP were particularly elevated in patients ≥40 years old. 

Interestingly, the proportion of patients with COVID-19-related liver injury at the first blood withdrawal after the first positive TA B L E 1 Patient characteristics and comparison between patients stratified for age (18- Figure 2 ). 

Assessed by log-rank test, elevated levels of AST (n = 194/543; 

In this study, we thoroughly characterized the patterns and trajectories of liver abnormalities in a large Austrian cohort of patients with COVID-19. Importantly, we identified the patient cohort of 40-69 years of age as a particularly vulnerable group for COVID-19-associated liver injury and liver-related death due to COVID-19. Moreover, in accordance with previous studies, 18 we identified increased levels of AST and BIL around the time of the first positive SARS-CoV-2 PCR test as an independent risk factor for mortality.

Both parameters of hepatocellular and of cholestatic liver injury progressively increased following SARS-CoV-2 infection, which is in line with previous studies. 12, 18 Subsequently, the liver chemistries, including AST and GGT regressed to pre-COVID infection levels.

Interestingly, ALP levels often remained elevated, suggesting prolonged/persistent cholestatic injury in a considerable number of patients with COVID-19. TA B L E 3 (Continued) TA B L E 3 Independent risk factors for mortality in COVID-19 patients between 40 and 69 years old. Next to the univariate analysis (i), multivariate models including (ii) aspartate transaminase (AST), (iii) gamma-glutamyl-transferase (GGT) and (iv) bilirubin at blood withdrawal after the first positive SARS-CoV-2 PCR are shown indicates that abnormalities of liver chemistries translate into worse liver-related outcomes. Thus, 40-69 years old patients with abnormal liver chemistries at COVID-19 diagnosis should be closely monitored, since they are at a particularly high risk for a severe course and worse outcomes.

Stratified for the severity of pre-existing liver disease, liverrelated mortality was highest in dACLD patients followed by non-ACLD and cACLD patients. This is in line with previous studies, which indicated an increased risk of liver-related complications particularly in dACLD patients. 32, 33 However, importantly, we also demonstrated that a small percentage (1.7%) of patients without pre-existing liver disease also died of liver-related causes, confirming that severe liver function impairment and acute liver failure is a rare but significant complication of COVID- 19. 3 Our observed association of elevated AST and BIL levels at COVID-19 diagnosis with mortality is in line with previous studies 18, 34 reporting the prognostic value of AST and BIL in patients with COVID-19. Especially elevated AST at the first blood withdrawal after the first SARS-CoV-2 PCR test seems to predict a severe course of COVID-19, 35, 36 since AST was associated with more frequent hospital admission, ICU admission and intubation in all age strata. In 40-69 years old patients, it was also linked to higher overall mortality, COVID-related death and liver-related death.

Our study also has limitations: firstly, due to the retrospective study design, selection bias cannot be ruled out. Second, not all parameters were available for all patients at all time points. However, the findings of this study are in line with the existing literature and the missing data is mostly attributable to patients without hospital admission. Thus, we are confident that our data is reflecting the clinical scenario of hospitalized patients with COVID-19. Thirdly, due to our monocentric study design, external validation of our results is required. Of note, this study mostly included unvaccinated patients 

Gilead and Intercept and is the coinventor of patents on the medical use of 24-norursodesoxycholic acid. M.M. served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Collective Acumen, Gilead and W. L. Gore & Associates and received travel support from AbbVie, Bristol-Myers Squibb and Gilead. T.R. received grant support from AbbVie

A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Pathophysiological mechanisms of liver injury in COVID-19

Features of 20 133 UKpatients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Liver injury during highly pathogenic human coronavirus infections

Review article: COVID-19 and liver disease-what we know on 1st

Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis

Involvement of liver in COVID-19: systematic review and meta-analysis

Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19

Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis

Clinical characteristics of coronavirus disease 2019 in China

COVID-19 and the liver: overview

COVID-19 and the liver

COVID-19 in a designated infectious diseases hospital outside Hubei Province

Association of liver abnormalities with in-hospital mortality in patients with COVID-19

Liver injury in COVID-19 -the culprit may not be COVID-19!

COVID-19: abnormal liver function tests

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

ACG clinical guideline: evaluation of abnormal liver chemistries

Risk factors for severe and critically ill COVID-19 patients: a review

Reiberger T Cirrhosis-associated RAS -inflammation -coagulation axis anomalies: parallels to severe COVID-19

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region

Post-COVID-19 cholangiopathy: a novel entity

Post-Covid-19 cholangiopathy-a new indication for liver transplantation: a case report

Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection

Factors associated with COVID-19-related death using OpenSAFELY

COVID-19) -United States

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 liver injury Spectrum study)

Longitudinal association between markers of liver injury and mortality in COVID-19 in China

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China